Sight Sciences Inc (SGHT) Stock Price, Quote & News

Company Profile

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients wi...

Industry: Medical Devices

Sector: Healthcare

Phone: 877 266 1144

Fax: 650 352 4401

Website: www.sightsciences.com

Address:

4040 Campbell Avenue, Suite 100, Menlo Park, United States

TerminalFlow Feb. 18 at 9:05 AM

$SGHT Clinical data cadence is the heartbeat here; silence usually means risk, not stability.

0 · Reply

RogueTrigger Feb. 18 at 6:54 AM

$SGHT Sight Sciences develops ophthalmic devices for glaucoma and dry eye, facing commercial execution scrutiny and competitive pressure from incumbents

0 · Reply

SignalVerdict Feb. 17 at 4:26 PM

$SGHT Sight Sciences develops ophthalmic devices for glaucoma and dry eye, facing commercial execution scrutiny and competitive pressure from incumbents

0 · Reply

OfficialStocktwitsUser Feb. 12 at 1:49 PM

$SGHT RSI: 31.06, MACD: -0.4044 Vol: 0.33, MA20: 6.17, MA50: 7.33 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OfficialStocktwitsUser Jan. 26 at 12:49 PM

$SGHT RSI: 25.99, MACD: -0.4288 Vol: 0.87, MA20: 7.33, MA50: 7.69 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PhishTourFunds Jan. 22 at 3:01 AM

$SGHT Still a gap underneath here to $5…

0 · Reply

DARKP00L Jan. 13 at 12:28 PM

$SGHT 07:15 on Jan. 13 2026 Sight Sciences Expects Q4 Total Revenue To Be $20.3M-$20.4M And FY25 Revenue To Be $77.3M- $77.4M #tradeideas

0 · Reply

PhishTourFunds Jan. 5 at 2:44 PM

$SGHT Analyst upgrade 👀

0 · Reply

OfficialStocktwitsUser Dec. 26 at 11:13 PM

$SGHT RSI: 63.60, MACD: 0.4746 Vol: 0.23, MA20: 8.39, MA50: 6.95 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

NephoscopeNote Dec. 26 at 5:48 PM

$SGHT Trading behavior shows investors weighing repeatability of results above expansion claims. Forecast discipline should become more precise and conservative. Clear execution would attract broader institutional participation. Stronger outcomes appear only when priorities stay focused.

0 · Reply

Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Jan 13, 2026, 7:05 AM EST - 5 weeks ago

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

Dec 31, 2025, 11:29 AM EST - 7 weeks ago

Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge

Nov 6, 2025, 10:16 PM EST - 3 months ago

Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 3 months ago

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Nov 6, 2025, 4:04 PM EST - 3 months ago

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

Nov 4, 2025, 4:05 PM EST - 3 months ago

Sight Sciences to Present at Two Upcoming Investor Conferences

Oct 23, 2025, 4:05 PM EDT - 4 months ago

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 17, 2025, 7:00 AM EDT - 4 months ago

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

Sep 17, 2025, 7:00 AM EDT - 5 months ago

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

Sep 10, 2025, 5:13 PM EDT - 5 months ago

Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 7:05 AM EDT - 5 months ago

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

Sep 2, 2025, 4:05 PM EDT - 6 months ago

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

Aug 26, 2025, 4:05 PM EDT - 6 months ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Aug 8, 2025, 6:48 AM EDT - 7 months ago

Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Jul 30, 2025, 7:00 AM EDT - 7 months ago

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

Jul 29, 2025, 7:00 AM EDT - 7 months ago

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

Jul 24, 2025, 4:05 PM EDT - 7 months ago

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

May 14, 2025, 4:05 PM EDT - 10 months ago

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

May 11, 2025, 1:26 AM EDT - 10 months ago

Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 10 months ago

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Apr 24, 2025, 4:05 PM EDT - 10 months ago

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Sight Sciences Announces the Release of its Sustainability Report

Apr 22, 2025, 4:05 PM EDT - 10 months ago

Sight Sciences Appoints Gary Burbach to its Board of Directors

Apr 21, 2025, 4:05 PM EDT - 11 months ago

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

Mar 25, 2025, 4:05 PM EDT - 11 months ago

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Mar 5, 2025, 10:06 PM EST - 1 year ago

Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Conference Call Transcript

Mar 5, 2025, 4:05 PM EST - 1 year ago

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

Feb 24, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Feb 19, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

Feb 13, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

Dec 19, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

Nov 19, 2024, 4:05 PM EST - 1 year ago

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 9, 2024, 1:32 PM EST - 1 year ago

Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:58 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In November

CMPS PACS

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Aug 3, 2024, 3:12 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

Jun 10, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Announces the Release of its First Sustainability Report

May 28, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

May 28, 2024, 8:30 AM EDT - 1 year ago

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

May 5, 2024, 1:58 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Apr 29, 2024, 8:05 AM EDT - 1 year ago

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Apr 10, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

$Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 2, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Mar 26, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

TerminalFlow Feb. 18 at 9:05 AM

$SGHT Clinical data cadence is the heartbeat here; silence usually means risk, not stability.

0 · Reply

RogueTrigger Feb. 18 at 6:54 AM

$SGHT Sight Sciences develops ophthalmic devices for glaucoma and dry eye, facing commercial execution scrutiny and competitive pressure from incumbents

0 · Reply

SignalVerdict Feb. 17 at 4:26 PM

$SGHT Sight Sciences develops ophthalmic devices for glaucoma and dry eye, facing commercial execution scrutiny and competitive pressure from incumbents

0 · Reply

OfficialStocktwitsUser Feb. 12 at 1:49 PM

0 · Reply

OfficialStocktwitsUser Jan. 26 at 12:49 PM

0 · Reply

PhishTourFunds Jan. 22 at 3:01 AM

$SGHT Still a gap underneath here to $5…

0 · Reply

DARKP00L Jan. 13 at 12:28 PM

$SGHT 07:15 on Jan. 13 2026 Sight Sciences Expects Q4 Total Revenue To Be $20.3M-$20.4M And FY25 Revenue To Be $77.3M- $77.4M #tradeideas

0 · Reply

PhishTourFunds Jan. 5 at 2:44 PM

$SGHT Analyst upgrade 👀

0 · Reply

OfficialStocktwitsUser Dec. 26 at 11:13 PM

0 · Reply

NephoscopeNote Dec. 26 at 5:48 PM

0 · Reply

anachartanalyst Dec. 23 at 5:01 PM

$SGHT https://anachart.com/wp-content/uploads/ana_temp/1766509290_soc-img.jpg

0 · Reply

Thestocktraderhubzee Dec. 23 at 3:22 PM

$SGHT UBS Maintains Buy on Sight Sciences, Raises Price Target to $12

0 · Reply

JarvisFlow Dec. 23 at 3:21 PM

UBS updates rating for Sight Sciences ( $SGHT ) to Buy, target set at 7 → 12.

0 · Reply

Doozio Dec. 22 at 3:59 PM

Unless yo a BLND dinglberry $USEA whuts $NXT during 🐒🍌🧠⏰♾️. $SGHT

0 · Reply

MichaelKTrades Dec. 20 at 10:29 AM

$SGHT Potential high tight flag forming. More than doubled within 8 weeks, now consolidating in a tight range less than 10% in a 3 week base, building higher lows. Note the high volume accumulation

0 · Reply

MichaelKTrades Dec. 18 at 9:56 PM

Market action is mixed IMO. Weaker inflation leads to further rate cuts and weaker USD $. May explain why silver and gold are hitting new highs. $GFI looks decent coming out of a multi week base. Other set ups for pilot buys if we rally $CSTL HTF $SGHT $PLTR

0 · Reply

JarvisFlow Dec. 11 at 9:05 PM

Citigroup has adjusted their stance on Sight Sciences ( $SGHT ), setting the rating to Neutral with a target price of 5.5 → 9.1.

0 · Reply

SuperGreenToday Dec. 11 at 12:12 AM

$SGHT Share Price: $8.45 Contract Selected: May 15, 2026 $10 Calls Buy Zone: $0.73 – $0.90 Target Zone: $1.38 – $1.68 Potential Upside: 79% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

JarvisFlow Dec. 10 at 7:00 PM

Lake Street updates rating for Sight Sciences ( $SGHT ) to Buy, target set at 7 → 12.

0 · Reply

Iaguy52155 Dec. 8 at 9:42 PM

$SGHT Whens this turd Goin dump?

0 · Reply

AnomalyDetective Dec. 8 at 5:57 PM

$SGHT taking another big bullish stair step higher in positive Segment 6 MDA breakout conditions. @vmbreakouts Also leading the Premium Portfolio higher +26.77% YTD trading in 19 fewer weeks than the #SPX S&P 500 by following the gauge signals. 👉More here: https://seekingalpha.com/article/4848825-rotations-continue-to-next-rally-as-markets-anticipate-january-effect

0 · Reply

JarvisFlow Dec. 2 at 5:56 PM

Morgan Stanley updates rating for Sight Sciences ( $SGHT ) to Equal-Weight, target set at 6 → 8.

0 · Reply

Market Cap	285.51M
Revenue (ttm)	79.87M
Net Income (ttm)	-51.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-64.49%
Debt to Equity Ratio	0.62

Volume	159,922
Avg Vol	281,736
Day's Range	N/A - N/A
Shares Out	52.87M
Stochastic %K	28%
Beta	2.41
Analysts	Strong Sell
Price Target	$9.35